Rezolute Joins the Rare Disease Company Coalition Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases

Rezolute Joins the Rare Disease Company Coalition

joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases

REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Rezolute,

Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to

disrupt current treatment paradigms for devastating metabolic diseases, today announced that it has joined the Rare Disease Company Coalition.

As an alliance of life science companies formed in May of 2021, the Rare Disease Company Coalition is committed to discovering, developing,

and delivering rare disease treatments for the patients they collectively serve.

"Rezolute is honored to be a part of the Rare Disease Company

Coalition and to join other companies that are mission driven to foster greater understanding of the specific challenges of rare disease

drug development," said Nevan Charles Elam, Chief Executive Officer, and Founder of Rezolute. Mr. Elam continued, "We believe

that the coalition is a great forum to advocate for the need to develop therapeutics for patients that suffer from serious diseases that

are often overlooked, and the promise of our work."

About the Rare Disease Company Coalition

The Rare Disease Company Coalition represents life science companies

committed to discovering, developing, and delivering rare disease treatments for the patients we serve. As an education and advocacy-focused

coalition of companies, our goal is to inform policymakers of the unique challenges and promises of rare disease drug discovery, development,

and manufacturing for small population sizes so that critical innovation can continue and positive changes can be enacted for the rare

disease community. To achieve this goal, we will use our unified voice to advocate for long-term, consistent, equitable and sustainable

government policies that enable life science companies to continue to bring hope and provide access to approved treatments to people living

with rare diseases. For more information, please visit www.rarecoalition.com.

About Rezolute, Inc.

Rezolute strives to disrupt current treatment paradigms by developing

transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential to both significantly

improve outcomes and reduce the treatment burden for patients, the treating physician, and the healthcare system. Patient, clinician,

and advocate voices are integrated in the Company's drug development process, enabling Rezolute to boldly address a range of severe

conditions. Rezolute is steadfast in its mission to create profound, positive, and lasting impact on patients' lives. The Company's

lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism, a rare pediatric endocrine disorder.

Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema. For more

Kimberly Minarovich/Carrie McKim

Canale Communications, Inc.